Showing posts with label International law. Show all posts
Showing posts with label International law. Show all posts

Tuesday, November 10, 2009

News Alert: Animal group welcomes UK House of Lords report on animal experimentation in the EU




For immediate release

10 th November 2009

Animal group welcomes the House of Lords report on animal experimentation in the EU

The BUAV, the UK 's leading organisation campaigning to end animal experiments, has today welcomed aspects of the report published by the House of Lords EU Committee. The Committee carried out an enquiry into proposals to revise EU Directive 86/609 on the protection of animals used in experiments.

The report is the result of an analysis of submissions of oral and written evidence provided by all stakeholders, including the European Commission, researchers, the pharmaceutical industry, academic and funding bodies representatives and animal protection groups including the BUAV. The Council of Ministers (EU Member States representatives) is currently discussing the European Commission proposals, and it is expected that it will adopt its position within the next few weeks.

The Committee's report shows their position is in line with the European Commission proposals. The BUAV believes this report shows promise and represents an improvement on the latest provisions adopted at the European Parliament last May and the current proposals on the table of the EU Council of Ministers.

The report contains some important provisions such as the requirement for all animal experiments to receive authorisation by governments and calls for strict limitations on the use of non-human primates (although the BUAV believes strongly, as does the public, that primates should not be used at all). Key conclusions include:

· the use of primates should be restricted to life threatening/debilitating conditions

· a move towards the use of second generation captive bred primates

· a ban on suffering which is severe and prolonged

· authorization by governments required for all procedures

However, the BUAV does not believe that the House of Lords has gone far enough; in particular regarding the need to avoid duplicative experiments and on the issue of the re-use of animals.

The BUAV is also calling for the directive to reflect public opinion. A recent opinion poll, carried out by YouGov, in the UK , France , Germany , Italy , Sweden and the Czech Republic found

· 81% of people surveyed agree or strongly agree the new law should prohibit all experiments causing pain or suffering to primates

· 79% of people agree or strongly agree the new law should prohibit all experiments on animals which do not relate to serious or life-threatening human conditions

· 84% of people surveyed agree or strongly agree the new law should prohibit all experiments causing severe pain or suffering to any animal

· 80% of people agree or strongly agree all information about animal experiments should be publicly available, except information which is confidential and information which would identify researchers or where they work

· 73% of people disagree or strongly disagree that the new law should permit experiments causing pain or suffering to cats

· 77% of people disagree or strongly disagree that the new law should permit experiments causing pain or suffering to dogs

BUAV's Chief Executive, Michelle Thew states: “This is a critical time for animals in laboratories across Europe . Although we welcome aspects of the House of Lords report, it would still leave a chasm between public opinion and the reality for laboratory animals'

For further information, please contact Carla Owen on +44 (0)207 619 6965 or Carla.owen@buav.org
or BUAV (out of hours) +44 (0)7850 510 955 or visit our Web site http://www.buav.org/


Notes:

1. All figures, unless otherwise stated, are from YouGov Plc. Total sample size was 7139 adults. Fieldwork was undertaken between 24th February - 4th March 2009. The survey was carried out online. The figures have been weighted and are representative of the population sizes of the countries surveyed.

2. The Lords has now submitted this report to the Home Office, as the Government Department in charge of the negotiating the UK position on the revised Directive. The Council of Ministers (EU Member States representatives) is currently discussing the European Commission proposals, and is expecting to adopt its position within the next months.

Friday, November 6, 2009

CRITICAL WEEK AS EUROPE DECIDES FUTURE OF LAB ANIMALS

Trialogue meeting to consider steps to end the capture of wild monkeys by dealers

Over the next few days the European Commission, European Parliament and Council of Ministers are holding trialogue discussions on new rules for animal experimentation throughout Europe. Key decisions will be made on whether to restrict primate use to certain areas of research and whether to stop the trapping of wild monkeys by dealers. The Council of Ministers' common position is expected in just two weeks.

At a meeting in the European Parliament yesterday, key MEPs examined shocking evidence, filmed by Animal Defenders International (ADI), showing the treatment of monkeys in animal testing labs and in supply facilities, and monkeys being caught in the wild for experiments. The meeting was also told how the latest scientific research shows that the monkeys most frequently used in Europe are now rapidly declining throughout their natural range.

Around 10,000 monkeys are used in experiments. Most of these monkeys are born of parents captured in the wild. Europe is therefore continuing to fuel the capture of thousands of wild monkeys to stock breeding farms in Asia.

A range of different perspectives was debated at yesterday's meeting in the European Parliament, which was hosted by Raul Romeva (Greens) with Shadow Rapporteur, Daciana Octavia Sarbu (S & D), also speaking.

ADI also showed examples of the latest alternatives to experiments on primates and called for the mechanisms under the new rules to ensure the development and implementation of replacements to experiments on animals.

Raul Romeva, MEP, said: "There can be no more excuses, it is time to act. A modern society will be judged according to the way it treats its animals. Thus, momentum is growing in Europe to protect animals from suffering. The animal welfare bills that have been proposed show that the will is there to take animal cruelty seriously. The terrible scenes of anguish and terror in the 'Save The Primates' film will force people to address this issue head-on, and make them question whether we can allow this animal cruelty to continue."

Tim Phillips, ADI Campaign Director, said: "This is the most important week in the animal experiment debate for over 20 years as Europe begins to finalise the new rules for experimentation with input from the Commission, Parliament, and Council of Ministers.
The decisions made will have an impact for years to come. It is vital that Europe has the courage to say clearly that tearing monkeys from the wild is unacceptable and that the EU is making a genuine commitment to replace the use of animals in experiments."

The new Directive for the protection of animals used for scientific purposes, which was proposed in 2008 to replace the outdated EC Directive 86/609/EC, provides the greatest opportunity in over 25 years to influence the use of animals, and in particular primates, in laboratories.

More than half of all MEPs in the European Parliament signed a Declaration in 2007, calling for a ban on the use of great apes and wild caught monkeys and for a timetable to phase out all primate experiments.

For more information, visit: www.savetheprimates.com


Ends


For all media enquiries contact: prdesk@ad-international.org
Media only, please
To make a donation: info@ad-international.org
or online here

For campaign information: info@ad-international.org

For employment opportunities: execassist@ad-international.org

For volunteer enquiries: execassist@ad-international.org

For Intern enquiries: intern@ad-international.org

General enquiries: info@ad-international.org

Sunday, October 18, 2009

3rd Circuit Rejects Online Activists' Free-Speech

Defense attorney says he expects the ruling will be appealed and is
'fairly sure we will wind up in the U.S. Supreme Court'
...
The First Amendment does not insulate animal rights activists from
criminal liability when they use an Internet Web site to orchestrate a
campaign of harassment, cyberattacks, vandalism and destruction of
property, the 3rd U.S. Circuit Court of Appeals has ruled.

In United States v. Fullmer, a three-judge panel unanimously refused
to strike down the Animal Enterprise Protection Act, rejecting
arguments by six activists -- convicted for targeting Huntingdon Life
Sciences, an animal testing firm -- who complained that the law had
effectively criminalized their legitimate political protests.

The ruling upholds convictions and prison terms for six members of
Stop Huntingdon Animal Cruelty, or SHAC, a group whose stated mission
was to drive Huntingdon Life Sciences out of business.

One of the judges wrote he would have overturned the protesters'
convictions on charges under the AEPA on non-constitutional grounds.

--
full story:
http://www.law.com/jsp/article.jsp?id=1202434647989&rd_Circuit_Rejects_Animal_Rights_Activists_Online_Speech_Challenge

Monday, August 3, 2009

Monkey trafficking into US: 1 January-30 June 2009

IPPL has received from the Fish and Wildlife Service the live primate
importation records dating from 1 January to 30 June, 2009. Anyone
wishing to receive a full Excel spread-sheet please send us their
private e-mail address. We are trying with no success to get
comparison matching data from CDC and Customs, the latter agency has
become extremely arrogant. We are not clear whether shipments
imported on US military planes would be declared, as no military
bases are named among the importers, and feel the number we have may
be a minimum. Other monkeys may come in as concealed cross-border
shipments by or under land borders, or by small boats. All imported
monkeys are fed into approved CDC quarantine stations unless a
facility maintains its own quarantine.

China is increasing its dominance as a supplier of a
non-native-to-China species (the crab-eating macaque) to world
markets. Either there are a lot of Chinese exporters or some dealers
use several names (maybe both). There are also suspicions that China
is importing monkeys from Cambodia for re-export under false
"captive-born" papers. Note that Houston is no longer a port of
entry. Los Angeles is by far the biggest port of entry for primates
as there are direct flights from China. Notable by their absence are
any great apes, all protected by their CITES Appendix I listing.

Note that very small numbers of monkeys are entering the United
States from Africa or South America.

There are two separate entries on the spread-sheet for imports by
Covance and Charles River, maybe due to the way the shipments are recorded.

Very few monkeys are imported these days by zoos. Omaha imported 14
black sakis from Guyana and Natural Bridge Zoo 8 spider monkeys from
Guatemala. It is illegal to import monkeys for the pet trade and to
the best of my knowledge no US sanctuary has a quarantine license so
international "rescues" are not feasible.

Primates by country of origin in descending order:

China: 7,308
Mauritius: 2,166
Vietnam: 1,559
Cambodia: 600
Philippines: 200
Saint Kitts and Nevis: 158
Israel: 120
Barbados: 36
Peru: 20
Guyana: 14
Guatemala: 8
France: 7
Canada, 1 (cross-border chimp transfer)
TOTAL: 12,197

By species in descending order:

Macaca fascicularis: 11,177 (crab-eating macaque aka long tailed macaque)
Macaca mulatta: 776 (rhesus macaque)
Chlorocebus aethiops: 194 (African green or vervet/grivet monkey)
Aotus nancymae: 20 (Owl monkey)
Chiropotes chiropotes: 14 (black saki monkey)
Ateles geoffroyi: 8 (spider monkey)
Microcebus murinus: 6 (mouse lemur)
Nomascus leocogenys: 1 (white-cheeked gibbon)
Pan troglodytes: 1 (cross-border in and out chimpanzee)

By port of entry in descending order:

Los Angeles: CA 7,789
Chicago, IL: 2,480
New York, NY: 1,334
Miami, FL: 214
San Francisco, CA: 200
Dulles Int'l. Airport: VA 90
Buffalo, NY: 76
Atlanta, GA: 14

By foreign exporter

1,878: Huazheng Laboratory Animal Breeding Center (China)
1,679: Nafovanny (Vietnam)
1,171: Bioculture Mauritius (Mauritius)
740: Guangzhou Blooming Spring Biological Technology Development (China)
720: Guangxi Weimei Bio-Tech Co. (China)
656: Beijing Piliyuan Trading Ltd. (China)
600: Angkor Primates Center (Cambodia)
509: Yunan Laboratory Primate Inc. (China)
500: Hainan Jingang Laboratory Animals Co., China)
480: Noveprim, (Mauritius)
360: Fang Cheng Gang Spring Biological Technology Development Co, (China)
280: China National Scientific Instruments (China)
275: Biodia Co. Ltd. (Mauritius)
240: Guangdong Landau Biotechnology Co. Ltd. (China)
240: Les Campches Ltee. (Mauritius)
240: Wing Freight Agent Ltd. Zhang Tao, (China)
200: Scientific Primates Filipinas, Inc. Vallestro, (Philippines)
181: Conghua City Yueyuan Animal Breeding Farm at Qigan (China)
164: Gaoyao Kangda Laboratory Animals Science and Technology Co. (China)
158: Primate Resources International (Kenya)
120: B.F.C - Monkey Breeding Farm (Israel)
120: Beijing Grandforest Trading Co. (China)
120: Beijing Ultimate Biosci. Co, (China)
120: Biomedical Research GZ), LTD. Wanpin Wen (China)
120: Guangdong Scientific Instruments and Materials Ye Yiyun, (China)
120: Suzhou Jin Nuo Import and Export Co. Ltd. (China)
120: Tianjin Jinxin Import and Export Corp. Ltd. (China)
36: Barbados Primate Research Center (Barbados)
20: Instituto de Investigaciones Tropicales y de Altura (Peru)
14: Bester Birds and Animal Zoo Park (South Africa)
8: Mascotas Exclusivas (Guatemala)
6: Museum National d'Histoire Naturelle (France)
1: Parc Zoologique de Cleres (France)

By US importer

4,377: Covance Research Products,
1,440: Charles River Lab
1,208: Charles River Laboratories, BRF
1,200: Covance Research Products, INC.
960: SNBL USA, LTD. (Japanese-based firm)
640: Harlan Sprague Dawley, Inc.
506: Worldwide Primates, Inc.
441: Primates Products, Inc.
360: Charles River Lab, Sierra Division
360: Shared Enterprises (Hsu)
200: New Iberia Research Center, University of Louisiana
164: Valley Biosystems, Inc.
116: Alphagenesis, Inc.
105: Buckshire Corporation
90: Bioreliance Katrina Camnara
14: Omaha's Henry Doorly Zoo
8: Natural Bridge Zoo
6: University of Texas at Austin
1: Gibbon Conservation Center
1: Steve Martin's Working Wildlife (one chimp, import/export, Canada)



Dr. Shirley McGreal, OBE, Chairwoman
International Primate Protection League
PO Box 766
Summerville, SC 29484, USA
Phone - 843-871-2280, Fax- 843-871-7988
E-mail - smcgreal@ippl.org, Web: www.ippl.org

"He who joyfully marches in rank and file has already earned my
contempt. He has been given a large brain by mistake, since for him
the spinal cord would suffice."
--Albert Einstein

Wednesday, July 29, 2009

Dr.Hadven Trust-Newsletter for July



'Roadmap to Replacement' needed, says the DHT, following 14% rise in animal experiments
The Dr Hadwen Trust was quick to respond to new Home Office statistics published July 21st that reveal a substantial rise in Britain's animal experiments. With 2009 marking the 50th anniversary of the birth of the 3Rs* (replacement, reduction and refinement of animal experiments) , far greater progress to replace animals with alternatives could and should have been made but instead animal numbers are now as high as they were in the late 1980s. The Dr Hadwen Trust said this was "a wake-up call moment for policy makers" and immediately wrote to the Prime Minister Gordon Brown, Conservative leader David Cameron, Lib Dem leader Nick Clegg and Green Party leader Dr Caroline Lucas, to seek political commitment to devising a national 'Roadmap to Replacement' .Animal research statistics 2008 at a glance
39% increase in animal experiments sinceLabour came to power in 1997
3.656 million animal experiments
3.583 million animals
14% rise in animal experiments
16% rise in experiments on GM animals
16% rise in monkey experiments
17% rise in cat experiments
9% rise in mice experiments
82% rise in experiments on amphibians
85% rise in fish experiments
95% rise in pig experiments
Decreases in use of dogs (-18%), rabbits (-13%)Click here to read our press release reaction...
* What are the 3Rs?In 1959 two British scientists, William Russell and Rex Burch, were the first to define the concept of the replacement, reduction and refinement of animal experiments, now adopted throughout much of the world and incorporated into legislation. Whilst the Dr Hadwen Trust's work focuses on the single 'R' of the replacement of animals, we recognise the enormous significance of the 3Rs concept in stimulating work on non-animal methods over the last fifty years.
DHT tells House of Lords Committee: EU needs new strategic vision to replace animals
In June the Dr Hadwen Trust's science policy team presented oral evidence to the House of Lords EU Committee as part of its consultation with experts on the Directive 86/609 proposals. The DHT told the Committee that policy makers must embrace the vision of a world where animal experiments have either been fully replaced or are prohibited, and that as a solutions-led charity the Dr Hadwen Trust works to find the science to achieve that vision. Once again we promoted the establishment of an EU Centre of Excellence in Alternatives, incorporating a new strategic vision of science for the future. We believe that establishing an EU Centre would be one of the most significant achievements of the revised Directive, setting strategic goals for replacement science across all areas of animal use. The Committee's newly published interim conclusions indicate that it agrees.Find out more...
7th World Congress on Alternatives
The Dr Hadwen Trust's science and policy team is gearing up for the 7th World Congress on Alternatives in Rome. This is the key event of the year attended by non-animal research scientists and experts from around the globe, providing a unique forum to meet, exchange ideas and create opportunities for international collaborations. We are delighted that nineDr Hadwen Trust-funded researchers will be presenting their cutting-edge replacement work at the Congress this year.Find out more...
Ricky Gervais, Joanna Lumley and other stars join cyber march for humane science
Comedian Ricky Gervais, actress and DHT Patron Joanna Lumley OBE and rockers Brian May CBE and Chrissie Hynde, have joined tens of thousands of people taking part in the Make Animal Testing History virtual march to Brussels to update the EU's 20-year old law on animal experiments. Click here to see the celebrity avatars cheering on the marchers; click each avatar to see what they have to say."With all the non-animal techniques available now and in the future, we really don't need to hurt animals to make medical progress."Ricky Gervais
Dr Hadwen Trust research wins non-animal replacement prize
Dr Hadwen Trust-funded researchers studying breast cancer have won a prestigious non-animal replacement prize at an event hosted by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) and held at the House of Lords. Our researchers at Leeds Institute of Molecular Medicine and Queen Mary's, University of London, constructed athree-dimensional model of human breast cancer in the test tube using human cells.Find out more...
Spotlight on life-saving research without animal suffering
Huntington's disease: Huntington's disease (HD) is an incurable inherited genetic disorder that affects the nervous system. Currently, much research into HD is conducted on monkeys, pigs and rodents injected with toxic chemicals or genetically modified to mimic symptoms. However, results have been conflicting and there have been no major therapeutic advances so far. Our research at Sheffield University aims to produce a new non-animal model of HD using human skin cells from HD patients. This would be far more useful for understanding the underlying cellular mechanisms that contribute to the disease and enable fast screening of potential drugs.
© Dr Hadwen Trustfor Humane Research18 Market PlaceHitchinHertsSG5 1DSUnited KingdomRegistered charity 261096
To subscribe to this e-newsletter click here.Privacy Policy - The Dr Hadwen Trust is committed to protecting your privacy and security. Whenever you provide personal information, we will treat that information in accordance with this policy, current UK Data Protection legislation and internet best practice. This information will only be used by the Dr Hadwen Trust.

> Latest news


> Science Room


> Join Us

Microlungs


Artificial "microlungs" grown using human lung tissue, could replace animal testing for lung toxicity for pharmaceuticals, chemicals and cosmetics. Find out more...


easyfundraising


Shop with easyfundraising for clothes, CDs, gifts and more from major brands, select the Dr Hadwen Trust as your cause and every purchase means a donation for us.


Donate now


At the Dr Hadwen Trust, we don't just hope for a world without animal experiments, we're making it happen. If you'd like to be a part of our mission to replace animal research with alternatives, please make a donation today...


JustGiving


If you're a fabulous fundraiser walking, climbing or cycling to raise funds for the Dr Hadwen Trust, set up a sponsorship page at JustGiving.


Welcome Candida and Adina


Dr Candida Nastrucci (left) is our new Science and Communications Officer. A scientist holding a DPhil in Clinical Biochemistry from the University of Oxford, Candida has expertise in Applied Molecular Biology and Biotechnology with an MSc from University College London (UCL) and a BSc. Hons. in Biochemistry with Biotechnology, from the University of Manchester Institute of Science and Technology (UMIST). She also has experience in post-doctoral research and teaching in academia, as well as animal charity work.


Adina Farmaner (right) has joined the Dr Hadwen Trust team as Fundraising Director. Adina brings with her 15 years experience working for charities such as Christian Aid, the RSPCA and Amnesty International UK, and she now hopes to unite her extensive fundraising experience with her passion for the DHT charity of which she has been a supporter for over 10 years.


The Dr Hadwen Trust is the UK's leading non-animal medical research charity, benefiting people and animals. If you are not already a member, join us today and help us put your ethics into action with vital medical research to replace animal experiments, like our Huntington's disease research project. You'll receive our quarterly members' magazine Alternative News as well as other exclusive benefits. With your help we can stop the suffering - thank you.

============ ========= ========= ========= ========= ========= =====
*Vivisection is a ‘costly distraction’*

http://www.scienceblog.com/cms/ blog/7769- why-do-we- need-do-animal- experiments- part-1-drug- discovery- 22800.html# comment-
Blog. 8 July 2009.
Animal experiments are a costly distraction in drugdevelopment.Despite extensive tests in animals, 92% of all potential newdrugs fail in clinical trials, usually becasue they do notwork or are unsafe, according to a white paper by the US FDA(Innovation or Stagnation: Challenge and Opportunity on theCritical Path to New Medical Products, 2004). In no other areaof science is the mantra repeated that a decades-oldtechnology is the best we have & will ever have!'The reason we use animal tests is because we have a comfortlevel with the process . . . not because it is the correctprocess, not because it gives us any real new information weneed to make decisions.' Melvin E. Andersen, director,computational systems biology, Hamner Institutes for HealthSciences, USA (quoted by Gaul, Washington Post, Saturday,April 12, 2008; Page A01).Intriguingly, a US National Research Council reportcommissioned by the US Environmental Protection Agency(Toxicity Testing in the 21st Century: A Vision and aStrategy, 2007) identified an urgent need to move from slow,expensive animal tests to more modern, more human-relevantmethods using human cells & tissues and computer programmes.The authors expected the 'paradigm shift' away from animaltests which they advocated to encounter resistance, astoxicological testing practices are 'deeply ingrained' andpressure to maintain the status quo is strong. Speaking toreporters at an American Association for the Advancement ofScience conference in 2008, after the launch of a tripleagency initiative to realise the goals outlined in the report,Christopher Austin, Director, US National Institutes of HealthChemical Genomics Center, said that 'Traditional animaltesting is expensive, time-consuming, uses a lot of animalsand from a scientific perspective the results do notnecessarily translate to humans. It’s a bold, ambitious thingto try to do but our goal is to eliminate animal use intoxicology in ten years.' More information about theinitiative can be found in Collins et al, Science, 319,906-907.Experts from academia & industry gathered at the Speed &Safety in Drug Discovery conference held at the Royal Societylast November were enthusiastic about the ability of thelatest in vitro, in silico and safer first-in-man technologiessuch as microdosing & microdialysis to out-perform thetraditional animal-based tests currently required by drugregulators (www.drugtestingcon ference.com) . They were alsovery supportive of an initiative to identify the best means ofpredicting human side effects. This could be achieved bytesting a panel of drugs for which both human and animal dataare already available in a battery of human biology-basedassays. The three data sets could then be compared to seewhether the human biology-based assays identified more of theeffects of drugs in humans than were identified by the animaltests. This comparison is called for by the Safety ofMedicines (Evaluation) Bill 2009.More information about new technologies in drug safety testingcan be found in our short film, Safer Medicines, freelyavailable on our website: www.safermedicines. org.Dr Margaret Clotworthy, Science Consultant, Safer MedicinesTrust.www.safermedicines. org/
"Tests on animals have led to around 100 drugs being thought potentially useful for stroke; not one has proved effective in humans. You don't need to be a balaclava-wearing animal rights activist to question the value of animal studies in this area of medical research." TheFirstPost. 25 January 2007.============ ========= ========= ========= ========= ===

"The ARISE Campaign: Animal Replacements Innovate Scientific Experimentation"

Stuart Chaifetz sent a message to the members of The ARISE Campaign: Animal Replacements Innovate Scientific Experimentation.
Subject: The New ARISE Blog 7/24/09
Hi everyone,Here is our latest blog. Check out the site for working links to the mentioned articles: http://www.facebook.com/l/
http://arisenj.blogspot.com/
Thanks!
And if you like what we are doing, please spread the word!Stuart ChaifetzProgram Director, the ARISE Campaign (Animal Replacements Innovate Scientific Experimentation) In the spirit of the Summer movie season, and its long history of producing sequels and trilogies, I would like to offer a third and final take on stories of research ‘breakthroughs’ being front page news, while failures are either never reported, or are dumped into the business section (grab a keg of soda and a garbage bag full of popcorn that cost more than the computer I am writing on if you really want to get that movie theater experience while reading this).In the course of my research on this issue, I found one exception to the rule that is stated above: For the first and perhaps last time, in May of 1998, scrutiny was poured over a front page story that over-promoted a supposed cure for cancer.The story “Cancer Drugs Face Long Road From Mice to Men” - published in the Los Angeles Times, May 6, 1998, was a direct response to this story - “HOPE IN THE LAB: A special report.; A Cautious Awe Greets Drugs That Eradicate Tumors in Mice,”which was printed on the front page of the NY Times three days earlier.There were two things that appear to have set off the counter-reaction to the NY Times story; a massive rush of people wanting to get the ‘cure,’ which didn’t exist, and the fact that the reporter who wrote the story created a possible conflict of interest by trying to get a book deal on it the next day. The Times itself was forced to cover the scandal:“...Peter Osnos, the publisher of Public Affairs Press, said: ''When a reporter writes a story that 24 hours later turns into a book proposal for which they're going to be paid a ton of money, that calls into a question the story they've written to begin with.”The LA Times story covering the controversy was something short of miraculous, for, once the glamor was lifted from the original article, a hard and honest look was finally taken regarding how cures in animals do not translate to cures in humans:“"The history of cancer research has been a history of curing cancer in the mouse," said Dr. Richard Klausner, director of the National Cancer Institute. "We have cured mice of cancer for decades--and it simply didn't work in humans."Recent medical history is rife with stories of cancer "cures," such as interferon, interleukin and taxol, that produced exciting results in animals and later proved disappointing in humans.Dr. LaMar McGinnis, an oncologist and medical consultant to the American Cancer Society, agreed. "We thought interferon was 'chicken soup' in the early '80s," he said. "I remember how excited everyone was; it seemed to work miracles in animals, but it didn't work in humans."”“"People do not understand how very far off this [clinical trials] is; these proteins are very difficult to make . . . and we are working very hard to make the human versions," Klausner said. "The mouse versions don't work in humans."”These statements are devastating to the pro-animal research lobby, but the question is this; eleven years after the NY Times debacle, has the media learn its lesson? In my opinion, no. Unfortunately, we still see screaming headlines telling us a cure for this disease or that one is just around the corner. And while that drives interest and support for research higher, these hopeful rays of light flash, fade, then dissolve into the darkness and reality that is the failure of animal research.

Saturday, July 25, 2009

Scientific assessment of chemical's toxicity - 28 chemicals tested

Scientific assessment of chemical's toxicity - 28 chemicals tested
with toxicogenomics



http://www.antidote-europe.org/substances_gb.htm




Scientific assessment of chemical's toxicity
28 chemicals tested with toxicogenomics

Introduction

The aim of this work is to introduce a method that is considered reliable
for assessing the toxicity of chemical substances. This goal of safety for
human health cannot be achieved through the use of standard toxicology
methods, which are still largely based on animal experiments. No animal
species is a biological model for another species, including man. This was
clearly demonstrated in the second half of the 20th century's discoveries in
the field of genetics. We can now define a species in terms of its
reproductive isolation which results from the fact that genes and
chromosomes are unique to each species and hence preclude reproduction
between different species. Genes determine protein synthesis and biological
functions. As any given species has a unique set of genes, it follows that
those biological functions will be species-specific.

Pennicillin kills guinea pigs whereas it has saved millions of humans ;
aspirin can cause birth defects in rats or dogs whereas this has not been
observed in humans. Many more examples illustrate the fact that no animal
species is a reliable model for another. Claude Bernard, the physiologist
who, in the 19th century, promulgated animal experiments as the main source
of knowledge for human medicine, stressed the similarities between animals
and humans, rather than the differences. He also justified his use of
animals on ethical grounds, as wanting to avoid experiments that could harm
humans.

We are now in the 21st century and possess many non-invasive methodologies
for the study of human medicine. Toxicological studies can be performed on
cultured human cells. In addition, for the past 15 years, we also possess
powerful new tools with which to monitor cells exposed to a given chemical -
DNA chips. These chips can reveal which genes are active in a cell at a
given time, even as soon as 24 hours after the cells have been exposed to
the test chemical. Knowing the function of these genes, we can observe the
response of the cell to the chemical and whether this response drives the
cell towards a pathological state. Toxicogenomics is the study of the genes
expressed following exposure to a chemical.

Antidote Europe has developed a novel approach to toxicogenomics by using
minituarized DNA chips, in combination with sequential exposure of two
different cell types, approximating what would occur in a whole body. We
have termed this approach "Scientific Toxicology Program" (STP) and what
follows are the results of 28 substances tested according to the STP.

Selection of test substances

France is the second largest consumer of pesticides in the world. One
hundred and fifty thousand people a year die in France from cancer. A
further 600,000 persons suffer from Alzheimer's disease and, in common with
other European countries, 15% of couples are infertile. Several renowned
researchers and medical scientists have pointed out that the widespread use
of chemicals is very likely the main cause of these shocking health
statistics. Greenpeace and the WWF have shown that dozens of chemicals are
present in the air we breathe in our homes. Worse still, chemicals in the
blood of pregnant mothers are 'off-loaded' on to the unborn foetus in the
womb. Yet, chemical manufacturers maintain that the link between chemical
use and disease has not been established.

In 2001, the European Commission launched the REACH (Registration,
Evaluation and Authorization of CHemicals) project, claiming that little or
no safety data existed with respect to almost 100,000 chemical substances
produced by industry. Following mounting pressure from manufacturers, this
number was subsequently reduced to 30,000 chemicals.

While acknowledging the need for such a project, Antidote Europe cautions
against the use of unreliable test methods for assessing toxic risk.
Classical toxicological methods still largely rely on animal experiments,
which, as we have explained, are not reliable for humans. Instead, we urge
the European Commission to incorporate STP as an integral part of its
testing strategy, based on human exposure data. Many observations have been
made following occupational or accidental exposure to chemicals. This should
be employed as a reference with respect to both the toxicity of these
chemicals and as a standard for the validation of relevant toxicological
methods. Since our aim was not to present the regulatory authorities with
data of unknown chemicals but simply to demonstrate the validity of STP, we
selected 28 chemicals already known or suspected of being toxic. We
therefore selected 15 pesticides (abamectin, aldicarb, aldrin, carbaryl,
chlorpyriphos, dicofol, fenazaquin, fipronil, heptachlor, lindane,
methoxychlor, paraquat, permethrin, phosmet and rotenone), 2 food additives
(benzoic acid -E210- and quinoline -E104-), 5 cosmetic ingredients
(3-aminophenol, 4-aminobiphenyl, 2-butoxyethanol, benzophenone-3 and propyl
paraben -E214-), 1 prescription drug (acetaminophen -paracetamol-) and 5
additional substances commonly used in industry (1,4-dioxane, acetonitril,
acrylamide, bisphenol A and ethylene glycol). Some of these substances are
multi-purpose. Although some of the pesticides have been banned in many
European countries, they may still be present in our environment and in our
water supply, thereby contaminating our bodies.

What is the STP ?

The first report on STP was published in Biogenic Amines, 2003, vol. 18, pp
41-54. STP is based on human cell cultures, DNA chips and knowledge of
genetics.

Culturing human cells has been routine in labs since about 1930. Some
centers, especially in Germany, the UK and the US, keep many different cell
lines obtained from human tissues and organs. These cells lines are
commercially available. In spite of being cancerous cells, their
characteristics are well known and they are used as biological models for
research worldwide. Our study used HepG2 liver cells and SH-SY5Y neuronal
cells. Once the culture box was covered by one layer of cells (a monolayer
of cells), the chemical to be tested was introduced and left in the culture
medium for 24 or 48 hours, at two different concentrations.

We chose liver cells because the liver, with its detoxifying function, is
crucially in contact with all chemicals circulating in the blood, and will
metabolize these chemicals in order to facilitate their elimination,
although this metabolism can result in substances becoming even more
dangerous than the original, depending on the enzymatic capability of the
liver. It is important to note that the enzymatic capability can differ
significantly between different animal species, which is one of the reasons
for the failure of animal-based toxicology with respect to humans. We chose
neuronal cells because many insecticides target the nervous system of their
victims and wanted to observe this effect on human cells.

A novel idea of our scientific team was to expose liver and neuronal cells
sequentially rather than in parallel, thus approximating the whole body
physiological response, in which the nervous system and other tissues and
organs are exposed to the metabolites circulating in the blood once the
liver has modified the original substances. And indeed we observed that some
of the tested chemicals did not elicit much response from the liver while
they (or rather their metabolites) significantly affected the neuronal
cells.

Another novel idea was to construct minituarized DNA chips containing 6
families of genes known to be implicated in the 6 metabolic pathways we had
selected for our study. These pathways were already known for their
association to particular diseases. Extensive literature already exists
regarding the role of each of these genes in normal cell metabolism, cycle
and function, as well as in pathological states. In contrast with the huge
number (many thousands of genes), expensive and time-consuming processes of
DNA chips developed in the US, for example, our cost-effective and very easy
to process minituarized DNA chips provide a key solution to the problem of
dealing with large automated platforms capable of testing tens of thousands
of substances (and many of their combinations) in reasonable time and cost
frames.

Our DNA chips contained 51 genes comprising 6 families, and designed for the
study of :

1. Cell stress : 5 genes for monitoring the response to oxidative stress
(GSS, GPX1, SOD1, GSTM3 and EPHX1), 2 genes implicated in the survival of a
cell in a stress situation (TRPM2 and HSPA9B) and 2 genes implicated in the
inflammatory response (PTGS2 -Vioxx's target- and NOS2A). If these genes are
elicited following the introduction of the substance to the culture medium,
it means the cell is under duress, and making attempts to repair cell
damage. The cell may subsequently 'commit suicide' if it cannot cope with
the damaging effects of the substance. According to the kind of damage and
if systemic mechanisms are not available for repair, exposed individuals
could develop different diseases : cancer, due to free radical activity,
inflammation or auto-immune disease, etc.

2. DNA damage : 3 genes implicated in DNA repair (RAD50, RAD51 and NFKB1), 3
genes preventing cell cycle (cell life and reproduction) following damage
(CDC25C, CDK4 and CDKN1) and 3 genes triggering apoptosis (cell death) if
the damage is not repaired (APAF1, ATM and BAX). If these genes are
themselves impaired, cells with damaged DNA will eventually grow and
multiply, resulting in cancer or developmental abnormalities, for example,
if systemic repair mechanisms are not available.

3. Cell cycle control : DNA replicates before cell division gives birth to
two cells, each receiving one copy of the original DNA. Many proteins have
crucial roles in the accurate and quality control of DNA replication as well
as in authorizing and controlling the progression of the cell cycle from
step to step. Our chips harboured 2 genes controlling cell proliferation
(FOS and JUN) and 7 genes implicated in stopping cell division and apoptotic
signal (BCL2, GADD45A, MDM2, TP53, EGF, PPARA and TUBA1). Abnormal
expression of these genes has been observed in cancer.

4. Neurotoxicity : 8 genes implicated (but not exclusively) in nerve
transmission and nervous system development (ACHE, CTSB, DRD2, TH, BZRP,
THBS1, HOXD1 and ROBO1). Abnormal expression of these genes, in the absence
of compensating mechanisms, could lead to neurological or even psychiatric
disorders, or malformations of nervous, muscular or cardiac systems if gene
expression is affected during foetal or early childhood development.

5. Hormonal response : ranging from glycaemia to reproduction, hormones
regulate many physiological functions. We have selected 10 genes under
hormonal control (TFF1, CTSD, PGR, RAN, AR, CREB1, ESR1, CALR, CYP19A1 and
ALB). Some of these genes code for steroid hormone receptors and their
deregulation could explain some of the increase in cases of genital
malformation, reduced male fertility and even breast or prostate cancer.

6. Protein conformation : the tridimensional structure of proteins is
crucial for their ability to perform their function. Correct amino acid
sequence but wrong folding is thought to lead to accumulation of non
functional proteins contributing to conformational diseases such as
Alzheimer's, type I diabetes, etc. Our chips harboured 6 genes implicated in
quality control of newly synthesized and cell loading of proteins (HSPA5,
XBP1, ATF6, ERN1, C12orf8 and A2M).

Results

Full results are available on our website or upon request from Antidote
Europe. Here, we present a brief summary of the reactions elicited by the
tested chemicals.

1. 1,4-dioxane : 3 out of the 6 marker families were impaired in liver
cells, all 6 families were impaired in neuronal cells, especially the cell
stress markers. This substance can lead to all 6 of the pathological
pathways explored.

2. 2-butoxyethanol : 41 of the 51 genes present on our DNA chips were
significantly repressed (for some of them, gene expression was reduced a
hundred-fold). All studied cellular functions were severely compromised in
both cell lines.

3. 3-aminophenol : 36 of the 51 genes were repressed, ten-fold for some of
them. All studied cellular functions were compromised in both cell lines.

4. 4-aminobiphenyl : 4 genes were overexpressed in liver cells (markers for
cell stress, DNA damage, cell cycle control and hormonal response) ; 25
genes were repressed in neuronal cells, in all 6 pathological pathways
explored.

5. Abamectin : 44 of the 51 genes were strongly repressed, a hundred-fold in
some cases. 27 genes were repressed in both cell lines. This insecticide
(targeting GABA synapses) has an unequivocal pathological potential.

6. Acetaminophen (paracetamol) : 30 genes were repressed quite strongly, 2
genes were overexpressed, affecting all cellular functions under study in
both cell lines.

7. Acetonitril : 2 genes were repressed and 3 overexpressed in liver cells
(markers for cell stress, DNA damage, cell cycle control, neurotoxicity and
hormonal response). 15 genes were repressed in neuronal cells, affecting all
studied cellular functions.

8. Benzoic acid (E210) : 38 of the 51 genes were repressed, significantly in
some cases. All studied cellular functions were disturbed in both cell
lines.

9. Acrylamide : 3 genes were overexpressed, 30 were repressed, significantly
in some cases. In neuronal cells, the response was mainly observed after
exposure to the highest dose. In contrast, liver cells were also affected at
low doses. All studied functions were affected in both cell lines.

10. Aldicarb : expression of 20 genes was affected in both cell lines and a
further 24 genes were affected in one or the other cell line, totalling 44
markers elicited. All studied cellular functions were affected in both cell
lines.

11. Aldrin : 14 genes were affected in liver cells, mainly overexpressed. 11
genes were affected in neuronal cells, of which, 2 were dramatically
overexpressed. All studied cellular functions were affected in both cell
lines, with very different reactions for each gene.

12. Benzophenone-3 : 2 genes were repressed (cell stress and neurotoxicity)
and 1 overexpressed (DNA damage) in liver cells. 16 genes were repressed in
neuronal cells, affecting all studied functions in this cell line.

13. Bisphenol A : 1 gene was repressed in liver cells after exposure to high
dose. 7 genes were overexpressed in liver cells after exposure to low dose.
20 genes were repressed in neuronal cells, affecting all studied functions.

14. Carbaryl : 4 genes were overexpressed and 7 were repressed in liver
cells, affecting all studied functions in this cell line. The effect was
dramatic on neuronal cells, in which 48 genes were significantly repressed
(a hundred-fold or more).

15. Chlorpyriphos : expression of 42 genes was affected in both cell lines
and a further 7 genes were affected in one or the other cell line, totalling
49 markers elicited out of the 51 harboured by our DNA chips. Genes were
repressed except for one neurotoxicity marker, which was overexpressed in
neuronal cells.

16. Dicofol : only one gene (a neurotoxicity marker) was slightly repressed
in liver cells. But 41 genes were repressed in neuronal cells, affecting all
studied functions in this cell line.

17. Ethylene glycol : 29 genes were repressed in liver cells, 48 genes were
repressed in neuronal cells, affecting all studied functions in both cell
lines.

18. Fenazaquin : 22 genes were strongly repressed in liver cells, 11 genes
were significantly repressed in neuronal cells, affecting all studied
functions in both cell lines.

19. Fipronil : 2 cell stress markers and 2 DNA damage markers were affected
in both cell lines ; 1 neurotoxicity and 1 hormonal response marker were
repressed in liver cells ; 1 cell cycle control, 2 hormonal response and 1
protein conformation marker were repressed in neuronal cells.

20. Heptachlor : 1 DNA damage marker was overexpressed in liver cells. 17
genes were repressed in neuronal cells, affecting all studied functions
mostly after low dose but long exposure time.

21. Lindane : 11 genes were repressed in both cell lines and another 32
genes were repressed in one or the other cell line, totalling 43 markers
repressed, thus affecting all studied functions in both cell lines.

22. Methoxychlor : 20 genes were affected in both cell lines and a further
23 genes were repressed in one or the other cell line, totalling 43 markers
elicited, thus affecting all studied functions in both cell lines. Except
for 1 overexpressed neurotoxicity marker in liver cells, fairly significant
repression was observed for all the other markers.

23. Paraquat : 46 genes were strongly repressed in both cell lines,
affecting all studied functions. Most dramatic effects were seen for DNA
damage and cell cycle control markers. For the long time exposure, most of
the elicited markers in neuronal cells were repressed a hundred-fold.

24. Permethrin : 7 genes were affected in liver cells, with respect to cell
stress, DNA damage and hormonal response functions. Neuronal cells were more
significantly affected, with 33 genes repressed, especially after long
exposure. All studied functions were affected in neuronal cells.

25. Phosmet : 2 genes wre overexpressed and 11 repressed in liver cells. 41
genes were significantly repressed in neuronal cells. All studied functions
were affected in both cell lines.

26. Propyl paraben (E214) : 6 out of 6 studied functions were affected in
both cell lines. Neurotoxicity markers were only slightly elicited in liver
cells.

27. Quinolin (E104) : 5 out 6 studied functions were affected in liver
cells, with most of elicited markers repressed two-fold. All studied
functions were affected in neuronal cells.

28. Rotenone : 29 genes repressed in liver cells, 27 in neuronal cells. The
most dramatic effects (hundred-fold repression) were observed on neuronal
cells after long exposure.

These being the first studies done with the STP, we do not have all the keys
for translating laboratory observations into specific prediction of disease
risk. However, we clearly see that each substance elicits a specific
response. In order to accurately hypothesize possible effects on the
individual, many parameters would have to be taken into account. For
example, water-soluble substances will easily circulate in body fluids and
be quickly eliminated whereas lipid-soluble ones will be stored in
adipocytes (fat cells) and can also remain in the lipidic sheaths of the
neuronal cells, thus posing a risk to potential target cells and tissues
over long periods of time. Whereas a substance capable of damaging the
central nervous system must cross the blood-brain barrier, a xenoestrogen
will easily reach its target simply by being transported in the blood, as is
the case with steroid hormones.

Effects already observed in humans

Clues about the validity of STP can be found by considering what is known
about the tested substances following human accidental or occupational
exposure. According to the International Agency for
Research in Cancer :
- workers exposed to 4-aminobiphenyl have developed bladder cancer
- urinary tract cancer has been observed in acetaminophen users in Australia
; others have reported hepatotoxicity of this drug
- nervous system problems have been observed in workers exposed to
acrylamide
- aldicarb has already been shown to induce DNA damage and mutations in
human cultured cells
- chromosomal aberrations have been induced by aldrin in cultured human
lymphocytes (white blood cells) ; aldrin inhibited intercellular
communication in human cell systems
- slight excess of lung cancer cases was observed in workers exposed to
heptachlor
- 4 cases of leukaemia were reported in men exposed to lindane ; cases of
aplastic anaemia have also been associated with exposure to lindane.
- P. Darbre et al have found parabens in tissue samples from breast tumors
and state that these chemicals are known xenoestrogens (J Appl Toxicol,
2004, 24, 1-4).
- Professor Charles Sultan states, after a study on exposure to pesticides,
that babies born to farmers have twice the normal risk of presenting genital
malformations.

All of this data is a small part of a much bigger picture since cancer,
neurological disorders and most of other diseases under consideration may
have very long latent periods of onset, and therefore the link between the
triggering substance and the disease will not be established as exposure
will have ceased long before the appearance of the first symptoms. However
initial these observations, they are nevertheless consistent with what could
be hypothesized as the chemical's effects on the basis of our STP results.

We can improve STP

The results presented here are the very first obtained with STP based on
limited resources. Many improvements are possible.

1. Cell types. For substances likely to be absorbed through inhalation or
feeding, lung and gut cells should be tested as these organs will be exposed
first. Blood and kidney cells should also be tested routinely. For very
important chemicals (prescription drugs, for example), STP could be a first
step before microdosing tests in healthy volunteers and could give more
valuable information than animal tests, after which only 1 drug out of 12
makes it to the market. STP is potentially a more powerful tool than QSAR
and other simulations since STP is not a simulation, but a direct
observation of what is taking place in human cells.

2. Markers. The human genome contains about 25,000 genes. About 1100 are
known to respond to chemical exposure. Although the 51 set selected for our
DNA chips have key functions in the processes we intended to study, there is
still room for a greater number of markers on chips designed to monitor
unexpected effects of substances.

3. Time and dose. Our results represent a snapshot of the state of gene
expressions 24 and 48 hours after the introduction of the test substance
into the culture medium. It would be interesting to observe more snapshots
at shorter, intermediate and longer periods of exposure. The same is true
for concentrations of test compounds, especially for suspected xenoestrogens
as the endocrine system is sensitive to infinitesimal doses.

Conclusion

As imperfect as it is, STP has already proven much more reliable that
animal-based toxicology and should replace it at once. Carcinogenicity
tests, which take several months and yield unreliable results in rodents,
can be performed in a few days with STP, in conjunction with other tests
(neurotoxicity, immunotoxicity, acute toxicity, etc.), thereby sparing the
lives of countless animals. STP has the advantage of dealing with human
genes, thus allowing the identification of sensitive individuals or groups
of individuals to a particular substance, based on our knowledge of human
polymorphism, unique to humans and not predictable through animal-based
toxicology.

With STP, automatization and optimisation of tests is possible at the very
early stages of a new chemical's development, thus allowing early screening
and disqualification of dangerous or ineffective substances, with consequent
gain of time and money. The short test times employed by STP would be able
to cope with the original 100,000 chemicals initially included in the REACH
project, and even many combinations of molecules (not feasible using on
animals), in a reasonable period of time (much less than the 12 years
considered by the European Commission for only 30,000 substances with the
current means).

With toxicogenomics programs receiving substantial funding in the US and
Japan, Europe should seriously consider allocating resources to improve STP
whose novel approach could put the EU at the cutting edge of this promising
new technology. These techniques are likely to become the standard in the
coming years, and manufacturers should help to implement them rather than
spending yet money on useless animal-based tests - and before public opinion
loses confidence in an industry that avoids using the best available
technology to assess the safety of its products.

http://www.antidote-europe.org/index.htm

Wednesday, July 22, 2009

Animal lab inspections cut and licences to experiment fast tracked as animal experiments rise

As the EU Council of Ministers considers new rules to govern animal experimentation across Europe, the Home Office have today released figures for animal experimentation in the UK, which reveal a massive increase in animal use.

Jan Creamer, Chief Executive of the National Anti-Vivisection Society (NAVS):
"It is a disgrace that in this age of sophisticated alternatives to animal use, and grave public concern over animal research, especially the use of primates, that the Government has allowed animal research to continue to rise in the UK. It is clear that the UK Home Office is failing to ensure that replacement techniques are fully implemented before licences are granted, as required by law. It is vital that the new rules being considered for Europe tackle this issue of adoption of new techniques and public accountability during the licensing process."

Whilst commercial animal testing has declined steadily in recent years, there has been a steady increase in the number of animals being used in speculative academic experiments in Universities.

In addition the creation of genetically modified animals is responsible for the steady rise in animal use in recent years.

The figures released today reveal that:
3.7 million experiments were performed on animals in 2008.
A rise of 454,000 - 14%
The breakdown of animals used is:
Primates: 4,598
Dogs: 6,105
Cats: 360
Mice: 2.4 million
Rats: 355,370
Rabbits: 17,060
Guinea pigs: 29,293
Horses: 9,365
GM animals: 1.3 million (genetically modified animals)

Jan Creamer: "There have been huge advances in the number of non-animal research techniques available yet this is simply not having the impact on animal use that it should. We need to see a real commitment from regulators to ensure that non-animal methods are used. The public wants good science without animal suffering and there is no reason for this not to be delivered."

Also released today is the Annual Report of the Home Office Animals Scientific Procedures Division (ASPD).

The ASPD report reveals that the Inspectorate recommended for approval 695 project licences in 2008, compared to 595 in 2007 - an increase of almost 17%.

Yet this coincided with a decrease in the number of laboratory inspections.
A fast-track system for personal licences to experiment on animals and short-term licences for students and overseas workers has been introduced.

There were 162 fast track personal licences issued in 2008, taking an average of just three days to process.

Jan Creamer: "We need better regulation on animal research, not less. People expect the Government to be steadily tightening the controls on animal research in favour of replacement with advanced technology, but instead they are steadily being relaxed.

"We revealed earlier this year how Home Office inspections of overseas monkey suppliers have allowed deplorable conditions. We have shown how commercial testing is fast tracked with no prior scrutiny from the Home Office. Now we learn that it is easier now to experiment on animals than it was ten years ago."
"The economics show us that good regulation and replacement with advanced technology is good for science and industry. The Government has not got the message yet."

----
Animal Defenders International
Millbank Tower
Millbank
LONDON, SW1P 4QP, UK
tel. +44 (0)20 7630 3340
fax. +44 (0)20 7828 2179
www.ad-international.org

www.ad-international.org

-----------------------------------------------
www.YouTube.com/AnimalDefenders

www.CafePress.com/AnimalDefenders

Saturday, July 18, 2009

New rules for safe shipping may save the whales




End of the line ... Nisshin Maru runs into threatening waters.
THE world's only factory whaling ship may be driven from the Antarctic by tighter regulations.

The Nisshin Maru is vital to the operations of the Japanese whaling fleet, but it will run foul of new rules imposed by the United Nations' International Maritime Organisation, an investigation by the Herald has found.

The ship will fall foul of three new measures that will apply in Antarctic waters: the heavy fuel oil it uses will be banned; its hull-strength and safety will fail new requirements; and its annual dumping of thousands of tonnes of offal at sea will be rejected in the global nature reserve.

The regulations were backed by the Antarctic Treaty System after a series of accidents involving tourism cruise ships, including the sinking of the MS Explorer.

They pose a dilemma for Japan, one of the world's largest and most law-abiding shipping nations, and threaten to make the operation of its heavily subsidised whaling fleet even more costly.

The 22-year-old Nisshin Maru weighs 8000 tonnes. It is owned by Kyodo Senpaku Kaisha, a company in Tokyo that is owned by the government-funded Institute of Cetacean Research.
Full story:


Sign our petition to replace animal testing in Europe!

ADI/NAVS have just launched a new petition to pressure the Council of
Ministers and the MEPs to improve the text voted in last May in the
European Parliament. The latter chose, to the great disappointment of
the public, progressive scientists and animal protection groups, to
considerably undermine some of the key articles of the Commission's
proposal.
Thus, the report voted by Neil Parish removes restrictions to primate
experiments, postpone indefinitely the ban on the use of wild-caught
primates and weakens the authorisation process, allowing vivisectors to
by-pass scientific good practice for more than 4 millions animals per
year. It also removes the upper-limit on pain, by allowing painful and
prolonged experiments and narrows the scope of the Directive to leave
some animals out of protection, for instance octopuses which are proved
to be sentient and able to feel pain just as vertebrates do.
These measures, pushed by powerful and narrow-minded industries blinded
by their short-term interests, will only slow down scientific progress
and the replacement of animal experiments. ADI/NAVS therefore calls on
the public in the UK, Europe and even the rest of the World to speak out
to roll-back the pharmaceutical lobby and support science and the
animals.
Our petition asks the European Parliament and the Council of Ministers
to ensure that the new Directive includes a ban on the use on Great Apes
and wild-caught primates, and restrictions on the use of other primates;
a prohibition of severe and prolonged suffering on animals in
experiments; an accountable, independent and transparent authorisation
process for all experiments; a licensing system for suppliers of
laboratory animals, establishments and individuals using animals;
bi-annual reviews to set targets for the replacement of animals in
particular tests; standards for husbandry and care that meet the
ethological needs of the animals and the establishment of an EU centre
for replacement of animal experiments.



Please sign it here: http://www.ad-international.org/petitions/
and
forward to all your friends and relatives for them to sign too. You can
also contact ADI/NAVS Supporter Relations on 020 7630 3340 and ask for a
paper form.
ADI PR Desk
Animal Defenders International
Millbank Tower
Millbank
LONDON, SW1P 4QP, UK
tel. +44 (0)20 7630 3340
fax. +44 (0)20 7828 2179
www.ad-international.org

http://www.ad-international.org/

-----------------------------------------------
www.YouTube.com/AnimalDefenders

www.CafePress.com/AnimalDefender

Friday, July 10, 2009

Japan Attempts to Bully the Netherlands

By Captain Paul Watson
It appears as though Japan may have finally succeeded in gaining enough influence in the Netherlands to attempt to dictate Dutch law.
Because the Steve Irwin, the Sea Shepherd Conservation Society’s flagship (used to obstruct activities by Japanese whalers in violation of international laws and in an internationally recognized Whale Sanctuary), is registered in the Netherlands, the Japanese authorities have lodged an official complaint regarding the conduct and behavior of the Steve Irwin.
In recent years, a number of incidents have taken place between the vessels of the Japanese whaling fleet and Sea Shepherd in the waters of the Southern Ocean Whale Sanctuary. According to the Dutch Transport and Water Management Inspectorate, both parties have been guilty of breaking international regulations concerning good seamanship and the safety at sea.
While it appears that this will not have any serious consequences for Japanese state-supported and illegal operations, it may carry serious consequences for Sea Shepherd.
On request of the Dutch Transport and Water Management Inspectorate, the Dutch Public Ministry investigated and determined it is not feasible to start a legal prosecution. The Dutch cabinet is now considering a ban against Sea Shepherd vessels sailing under the Dutch flag. Public Works State Secretary Tineke Huizinga said she wants to amend the law quickly to make this possible.
Japan has repeatedly complained to the Netherlands about Sea Shepherd. Current law makes it difficult to take action against ships already registered with the Dutch government, so the cabinet wants to speedily extend its legal options for withdrawing certificates of registry, according to Huizinga.
Unfortunately, the Dutch authorities would be closing their eyes to the fact that all the incidents between the illegal Japanese whalers and Sea Shepherd have taken place in the waters of the Southern Ocean Whale Sanctuary and/or in others areas protected by international and Australian Federal law.
The Japanese whaling fleet is engaged in illegal activities, but lack of enforcement allows them to operate largely unopposed. Sea Shepherd is the only organization actively enforcing conservation law to stop these Antarctic poachers, and operates under the UN World Charter for Nature to that end.
For years now the Netherlands have stated they are against whaling, but have not taken any action to back up this statement. Now, given the opportunity to stand up to Japan, they intend to persecute the only organization worldwide actively striving to enforce international laws and protect whales.
Why does the Dutch government not show its independence and acknowledge the violations of the law committed by the Japanese whalers? Why is Japan apparently placed above international law?
Japan has placed itself above the law because it assumes no government in the world would show the will to actively accuse and legally prosecute Japan for their many violations of international conservation laws. The only entity that has dared to stand up and act is Sea Shepherd. The Netherlands now has an opportunity to join the legal and ethical side in this battle.
Will the Dutch government narrow-mindedly support illegal whaling operations, or will they support the only organization actively seeking to uphold those same laws by not pandering to Japanese objections?
It seems that Japan is attempting to amend Dutch law. We hope we are wrong. Regardless, we will continue to defend the defenseless against illegal activities in the Antarctic and elsewhere.